These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 11072597)
21. Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: a prospective, controlled pilot study. Gragnani L; Fabbrizzi A; Triboli E; Urraro T; Boldrini B; Fognani E; Piluso A; Caini P; Ranieri J; Monti M; Laffi G; Zignego AL Dig Liver Dis; 2014 Sep; 46(9):833-7. PubMed ID: 24953206 [TBL] [Abstract][Full Text] [Related]
22. Pilot study on the safety and efficacy of intravenous natural beta-interferon therapy in patients with chronic hepatitis C unresponsive to alpha-interferon. Mazzoran L; Grassi G; Giacca M; Gerini U; Baracetti S; Fanni-Canelles M; Zorat F; Pozzato G Ital J Gastroenterol Hepatol; 1997 Aug; 29(4):338-42. PubMed ID: 9476188 [TBL] [Abstract][Full Text] [Related]
23. Genetic complexity of the hypervariable region 1 (HVR1) of hepatitis C virus (HCV): influence on the characteristics of the infection and responses to interferon alfa therapy in patients with chronic hepatitis C. Pawlotsky JM; Pellerin M; Bouvier M; Roudot-Thoraval F; Germanidis G; Bastie A; Darthuy F; Rémiré J; Soussy CJ; Dhumeaux D J Med Virol; 1998 Apr; 54(4):256-64. PubMed ID: 9557291 [TBL] [Abstract][Full Text] [Related]
24. Clinical impact of genotype 1 TT virus infection in patients with chronic hepatitis C and response of TT virus to alpha-interferon. Nishizawa Y; Tanaka E; Orii K; Rokuhara A; Ichijo T; Yoshizawa K; Kiyosawa K J Gastroenterol Hepatol; 2000 Nov; 15(11):1292-7. PubMed ID: 11129224 [TBL] [Abstract][Full Text] [Related]
25. Interferon retreatment in chronic hepatitis C: which patients to choose, and what schedule to use. Picciotto A; Campo N; Brizzolara R; Sinelli N; Torre F; Cipriani AG; Ponassi I; Varagona G; Grasso A; De Leo P; De Conca V; Mesiti S; Marenco G; Menardo G; Dodero M; Celle G Eur J Gastroenterol Hepatol; 1999 Jun; 11(6):649-53. PubMed ID: 10418937 [TBL] [Abstract][Full Text] [Related]
26. Longterm efficacy of interferon-alpha for extrahepatic disease associated with hepatitis C virus infection. Naarendorp M; Kallemuchikkal U; Nuovo GJ; Gorevic PD J Rheumatol; 2001 Nov; 28(11):2466-73. PubMed ID: 11708420 [TBL] [Abstract][Full Text] [Related]
27. [Active arthritis due to cryoglobulinemia based on HCV infection in a patient with RA improvement of arthritis with IFN-alpha]. Tsujimura S; Saito K; Tokunaga M; Nakatsuka K; Nakayamada S; Nakano K; Sawamukai N; Nawata M; Tanaka Y Nihon Rinsho Meneki Gakkai Kaishi; 2004 Feb; 27(1):48-53. PubMed ID: 15045816 [TBL] [Abstract][Full Text] [Related]
28. Long-term clinical and virological outcomes of chronic hepatitis C after successful interferon therapy. Tsuda N; Yuki N; Mochizuki K; Nagaoka T; Yamashiro M; Omura M; Hikiji K; Kato M J Med Virol; 2004 Nov; 74(3):406-13. PubMed ID: 15368524 [TBL] [Abstract][Full Text] [Related]
29. Clinical significance of hepatic HCV RNA in patients with chronic hepatitis C demonstrating long-term sustained response to interferon-alpha therapy. Larghi A; Tagger A; Crosignani A; Ribero ML; Bruno S; Portera G; Battezzati PM; Maggioni M; Fasola M; Zuin M; Podda M J Med Virol; 1998 May; 55(1):7-11. PubMed ID: 9580879 [TBL] [Abstract][Full Text] [Related]
30. Assessment, by transcription-mediated amplification, of virologic response in patients with chronic hepatitis C virus treated with peginterferon alpha-2a. Sarrazin C; Hendricks DA; Sedarati F; Zeuzem S J Clin Microbiol; 2001 Aug; 39(8):2850-5. PubMed ID: 11474002 [TBL] [Abstract][Full Text] [Related]
31. Re-treatment of patients with hepatitis C who failed to respond (nonresponders) to previous treatment. Sharvadze LG; Gogichaishvili ShSh; Sakandelidze TsG; Zhamutashvili MT; Chkhartishvili NI Georgian Med News; 2009 Jan; (166):61-4. PubMed ID: 19202222 [TBL] [Abstract][Full Text] [Related]
32. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin. Yu JW; Wang GQ; Sun LJ; Li XG; Li SC J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637 [TBL] [Abstract][Full Text] [Related]
33. Occult HBV infection and suppression of HCV replication in the early phase of combination therapy for chronic hepatitis C. Ferraro D; Bonura C; Giglio M; Di Stefano R; Almasio PL; Di Marco V; Craxì A; Cacciola I; Squadrito G; Raimondo G J Biol Regul Homeost Agents; 2003; 17(2):172-5. PubMed ID: 14518718 [TBL] [Abstract][Full Text] [Related]
34. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin. Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916 [TBL] [Abstract][Full Text] [Related]
35. Successful treatment of hepatitis C reinfection with interferon-alpha2b and ribavirin after liver transplantation. Yedibela S; Schuppan D; Müller V; Schellerer V; Tannapfel A; Hohenberger W; Meyer T Liver Int; 2005 Aug; 25(4):717-22. PubMed ID: 15998420 [TBL] [Abstract][Full Text] [Related]
36. Late disappearance of hepatitis C virus RNA from peripheral blood mononuclear cells in patients with chronic hepatitis C in sustained response after alpha-interferon therapy. García-Bengoechea M; Basaras M; Barrio J; Arrese E; Montalvo II; Arenas JI; Cisterna R Am J Gastroenterol; 1999 Jul; 94(7):1902-5. PubMed ID: 10406257 [TBL] [Abstract][Full Text] [Related]
37. Correlates and prognostic value of the first-phase hepatitis C virus RNA kinetics during treatment. Durante-Mangoni E; Zampino R; Portella G; Adinolfi LE; Utili R; Ruggiero G Clin Infect Dis; 2009 Aug; 49(4):498-506. PubMed ID: 19591593 [TBL] [Abstract][Full Text] [Related]
38. A simple rule to personalize standard dual therapy across all genotypes in naive chronic hepatitis C patients: the TT4 randomized trial. Francioso S; Almerighi C; Forte P; Bandiera F; Nosotti L; Lionetti R; Taliani G; Piras MR; Ponti ML; Parruti G; Di Candilo F; Gentile S; Piccolo P; Salso A; Riccobelli F; Renzi S; Longo MA; Montalbano M; Zaru S; Biliotti E; Di Masi F; Santopaolo F; Angelico M Dig Liver Dis; 2014 Feb; 46(2):164-9. PubMed ID: 24239044 [TBL] [Abstract][Full Text] [Related]
39. Chronic hepatitis C. Genotypes and response to anti-viral therapy among Saudi patients. Al-Traif I; Handoo FA; Al-Jumah A; Al-Nasser M Saudi Med J; 2004 Dec; 25(12):1935-8. PubMed ID: 15711670 [TBL] [Abstract][Full Text] [Related]
40. Twenty-four weeks of pegylated interferon plus ribavirin effectively treat patients with HCV genotype 6a. Zhou YQ; Wang XH; Hong GH; Zhu Y; Zhang XQ; Hu YJ; Mao Q J Viral Hepat; 2011 Aug; 18(8):595-600. PubMed ID: 21105968 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]